Price T Rowe Associates Inc Ascendis Pharma A/S Transaction History

Price T Rowe Associates Inc

  • $812 Billion
  • Q1 2025

A detailed history of Price T Rowe Associates Inc transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Price T Rowe Associates Inc holds 2,256,102 shares of ASND stock, worth $442 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
2,256,102
Previous 2,283,207 1.19%
Holding current value
$442 Million
Previous $314 Million 11.87%
% of portfolio
0.04%
Previous 0.04%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 14, 2025
SELL
$119.49 - $168.84 $3.24 Million - $4.58 Million
-27,105 Reduced 1.19%
2,256,102 $352 Million
Q4 2024

Feb 14, 2025
BUY
$122.0 - $146.6 $19.8 Million - $23.8 Million
162,079 Added 7.64%
2,283,207 $314 Million
Q3 2024

Nov 14, 2024
BUY
$113.0 - $153.43 $38.1 Million - $51.7 Million
336,980 Added 18.89%
2,121,128 $317 Million
Q2 2024

Aug 14, 2024
BUY
$121.07 - $153.67 $269,017 - $341,454
2,222 Added 0.12%
1,784,148 $243 Million
Q1 2024

May 15, 2024
BUY
$123.45 - $159.4 $41.6 Million - $53.7 Million
336,976 Added 23.32%
1,781,926 $269 Million
Q4 2023

Feb 14, 2024
SELL
$86.1 - $127.36 $16.6 Million - $24.6 Million
-192,898 Reduced 11.78%
1,444,950 $182 Million
Q3 2023

Nov 14, 2023
SELL
$86.5 - $103.97 $36.3 Million - $43.6 Million
-419,316 Reduced 20.38%
1,637,848 $153 Million
Q2 2023

Aug 14, 2023
SELL
$69.96 - $97.84 $91.8 Million - $128 Million
-1,312,779 Reduced 38.96%
2,057,164 $184 Million
Q1 2023

May 15, 2023
SELL
$104.9 - $126.78 $35.7 Million - $43.1 Million
-339,898 Reduced 9.16%
3,369,943 $361 Million
Q4 2022

Feb 14, 2023
SELL
$99.42 - $131.97 $16.4 Million - $21.8 Million
-165,022 Reduced 4.26%
3,709,841 $453 Million
Q3 2022

Nov 14, 2022
SELL
$84.03 - $110.23 $108 Million - $142 Million
-1,290,512 Reduced 24.98%
3,874,863 $400 Million
Q2 2022

Aug 15, 2022
BUY
$78.08 - $117.61 $23.1 Million - $34.7 Million
295,224 Added 6.06%
5,165,375 $480 Million
Q1 2022

May 16, 2022
BUY
$102.18 - $135.75 $11.1 Million - $14.8 Million
108,958 Added 2.29%
4,870,151 $572 Million
Q4 2021

Feb 14, 2022
SELL
$127.1 - $169.66 $9.47 Million - $12.6 Million
-74,521 Reduced 1.54%
4,761,193 $641 Million
Q3 2021

Nov 15, 2021
SELL
$112.67 - $176.92 $25.4 Million - $39.9 Million
-225,540 Reduced 4.46%
4,835,714 $771 Million
Q2 2021

Aug 16, 2021
SELL
$121.62 - $145.29 $1.47 Million - $1.76 Million
-12,082 Reduced 0.24%
5,061,254 $666 Million
Q1 2021

May 17, 2021
SELL
$124.92 - $173.33 $193 Million - $268 Million
-1,545,706 Reduced 23.35%
5,073,336 $654 Million
Q4 2020

Feb 16, 2021
BUY
$151.2 - $182.76 $1 Billion - $1.21 Billion
6,619,042 New
6,619,042 $1.1 Billion

Others Institutions Holding ASND

# of Institutions
280
Shares Held
61.6M
Call Options Held
202K
Put Options Held
201K
View Full List

About Ascendis Pharma A/S

ASND Quotes by TradingView
  • Ticker ASND
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,810,200
  • Market Cap $10.9B
  • Description
  • Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...
More about ASND
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email